Bicycle Therapeutics Plc (BCYC) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.1x

Market Cap

$292.57M

MomentumView details →

1D Return

−2.79%

YTD Return

−40.18%

RSI (14)

52.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.1x

Market Cap

$292.57M

RSI (14)

52.5

MomentumView details →

1D Return

−2.79%

YTD Return

−40.18%

SummaryUpdated Jun 1, 2026

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, United Kingdom. The company went public on NASDAQ in May 2019, raising capital to advance its innovative bicycle peptide drug platform. Bicycle Therapeutics specializes in developing a novel class of medicines called bicycle peptides, which are designed to address diseases that are poorly served by existing therapeutic options, particularly in oncology and other therapeutic areas.

Ask drillr about Bicycle Therapeutics Plc →

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−311.11%

EBITDA Margin

−299.32%

ROE (TTM)

−37.32%

ROA (TTM)

−31.39%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

+217.44%

EPS YoY

+22.00%

FCF YoY

+2.39%

Revenue CAGR 3Y

+71.21%

EPS CAGR 3Y

−8.59%

EBITDA YoY

+30.83%

EarningsView details →

EPS (Actual)

−$0.72

EPS Surprise

−27.59%

Beats (12Q)

6/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

4.55%

Rev Surprise

−85.10%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

12.08x

Quick Ratio

12.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

61.20M

Net Income (TTM)

−190.41M

Op. CF (TTM)

−205.72M

Next earningsOct 29, 2026 →

Latest newsMore news →

Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.20d ago

Bicycle Therapeutics PLC reported financial results for the second quarter of 2026, with collaboration revenue of $629,000 and a net loss of $50.3 million.41d ago

Similar companies

Entrada Therapeutics, Inc.TRDA Adagene Inc.ADAG Fulcrum Therapeutics, Inc.FULC ProQR Therapeutics N.V.PRQR Foghorn Therapeutics Inc.FHTX Fate Therapeutics, Inc.FATE Find similar companies →

Latest newsMore news →

Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.20d ago Bicycle Therapeutics PLC reported financial results for the second quarter of 2026, with collaboration revenue of $629,000 and a net loss of $50.3 million.41d ago